Andrew Layton is a director in Guidehouse’s Life Sciences practice, joining the Firm through Guidehouse's acquisition of Quorum Consulting, a full-service Life Science reimbursement consulting firm.
Andrew functions as a key member of Guidehouse’s Market Access team. He is an expert in applying data to reimbursement policy initiatives and helped numerous companies attain new technology add-on payments, new MS-DRG assignments and new APC assignments. Andrew specializes in analyzing CMS data including MedPAR, OPPS, and the Standard Analytical Files. His recent work includes papers published in the Journal of Vascular and Interventional Radiology, Allergy and Asthma Proceedings, and Clinical Lung Cancer.
Andrew also applies his data analytics capabilities to Guidehouse’s HUB Programs & Services technology platform. His focus is to take the data acquired through HUB programs and services, apply business intelligence and behavioral analytics to generate meaningful client and provider data dashboards for benchmarking and payer-based engagements.
Prior to joining Quorum Consulting, Andrew successfully ran his own consulting company for over 5 years.